157,995 Shares in Omnicell, Inc. $OMCL Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 157,995 shares of the company’s stock, valued at approximately $6,560,000. Connor Clark & Lunn Investment Management Ltd. owned 0.35% of Omnicell as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares during the period. Cerity Partners LLC increased its position in shares of Omnicell by 4.9% during the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock valued at $345,000 after purchasing an additional 354 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Omnicell by 1.2% during the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after purchasing an additional 424 shares during the period. Legal & General Group Plc raised its stake in shares of Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after purchasing an additional 448 shares in the last quarter. Finally, California State Teachers Retirement System raised its stake in shares of Omnicell by 1.7% in the second quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock valued at $1,251,000 after purchasing an additional 692 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on OMCL shares. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research note on Monday. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Wells Fargo & Company decreased their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $33.45 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The business’s fifty day moving average price is $40.04 and its two-hundred day moving average price is $39.40. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 39.82, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same period last year, the business earned $0.45 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.